SCOPUS 정보 검색 플랫폼

Volumn 38, Issue 11, 2000, Pages 81-86

Are rofecoxib and celecoxib safer nsaids?

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CARBAMAZEPINE; CELECOXIB; CORTICOSTEROID; CREATININE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN DERIVATIVE; CYTOCHROME P450 2C9; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ETODOLAC; FLUCONAZOLE; IBUPROFEN; LITHIUM; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PLACEBO; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; RIFAMPICIN; ROFECOXIB; SULFONAMIDE; TACROLIMUS; WARFARIN;

ANGIONEUROTIC EDEMA; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLEEDING; BRONCHOSPASM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM ULCER; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG POTENCY; DRUG SAFETY; ENZYME INHIBITION; EPIGASTRIC PAIN; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEARTBURN; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; OSTEOARTHRITIS; PROSTAGLANDIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SKIN TOXICITY; SLOW RELEASE FORMULATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS; CYCLOOXYGENASE INHIBITORS; HUMANS; LACTONES; PYRAZOLES; SULFONAMIDES; SULFONES;

EID: 0033693145 PISSN: 00126543 EISSN: None Source Type: Journal
DOI: None Document Type: Article

Times cited : (16)

References (36)

1
- 0001023001
- Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2
- (Oxford)
- (1999) Rheumatology , vol.38 , pp. 779-788
- Brooks, P.¹ Emery, P.² Evans, J.F.³

2
- 0032066149
- NSAID induced gastrointestinal complications: The ARAMIS perspective-1997
- (1998) J Rheumatol , vol.25 , Issue.SUPPL. 51 , pp. 8-16
- Singh, G.¹ Rosen Ramey, D.²

3
- 0033963437
- Quantitative estimation of rare adverse events which follow a biological progression: A new model applied to chronic NSAID use
- (2000) Pain , vol.85 , pp. 169-182
- Tramer, M.R.¹ Moore, R.A.² Reynolds, D.J.M.³ McQuay, H.J.⁴

4
- 0029162250
- Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial
- (1995) Ann Intern Med , vol.123 , pp. 241-249
- Silverstein, F.E.¹ Graham, D.Y.² Senior, J.R.³

5
- 0028353941
- Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs
- (1994) Lancet , vol.343 , pp. 1075-1078
- Langman, M.J.S.¹ Weil, J.² Wainwright, P.³

6
- 0028327671
- Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs
- (1994) Lancet , vol.343 , pp. 769-772
- Garcia Rodriguez, L.A.¹ Jick, H.²

7
- 0034041077
- Basic biology and clinical application of specific cyclooxygenase-2 inhibitors
- (2000) Arthritis Rheum , vol.43 , pp. 4-13
- Crofford, L.J.¹ Lipsky, P.E.² Brooks, P.³ Abramson, S.B.⁴ Simon, L.S.⁵ van de Putte, L.B.A.⁶

8
- 0034189392
- Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor
- (2000) Am J Ther , vol.7 , pp. 159-175
- Whelton, A.¹ Maurath, C.J.² Verburg, K.M.³ Geis, G.S.⁴

9
- 0033594911
- Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis
- (1999) Proc Natl Acad Sci USA , vol.96 , pp. 7563-7568
- Warner, T.D.¹ Giuliano, F.² Vojnovic, J.³ Bukasa, A.⁴ Mitchell, J.A.⁵ Vane, J.R.⁶

10
- 0007095730
- Vioxx. Summary of Product Characteristics, UK. Merck Sharp and Dohme Limited, April
- (2000)

11
- 0033064312
- Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model
- (1999) Clin Pharmacol Ther , vol.65 , pp. 336-347
- Ehrich, E.W.¹ Dallob, A.² De Lepeleire, I.³

12
- 0032885911
- Rofecoxib
- (1999) Drugs , vol.58 , pp. 499-505
- Scott, L.J.¹ Lamb, H.M.²

13
- 0007003919
- Comparative inhibitory activity of rofecoxib (Vioxx), meloxicam, diclofenac, ibuprofen and naproxen on COX-2 versus COX-1 in healthy female volunteers. XIV EULAR Congress, Glasgow, June 6-11, Poster 857.
- (1999)
- Schwartz, J.I.¹ Van Hecken, A.² De Lepeliere, I.³

14
- 0034717664
- A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis
- For the Rofecoxib/Ibuprofen Comparator Study Group.
- (2000) Arch Intern Med , vol.160 , pp. 1781-1787
- Day, R.¹ Morrison, B.² Luza, A.³

15
- 0034041594
- Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium. Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip
- For the Rofecoxib Phase III Protocol 035 Study Group.
- (2000) Arthritis Rheum , vol.43 , pp. 978-987
- Cannon, G.W.¹ Caldwell, J.R.² Holt, P.³

16
- 0032744460
- The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis
- (1999) Clin Ther , vol.21 , pp. 1688-1702
- Schnitzer, T.J.¹ Truitt, K.² Fleischman, R.³

17
- 0007096394
- VIGOR: Landmark study confirms superior GI safety profile with rofecoxib. A report from Digestive Disease Week Congress. San Diego, California, USA. 24 May [poster]
- (2000)

18
- 0001175594
- Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen
- (1999) Aliment Pharmacol Ther , vol.13 , pp. 761-767
- Lanza, F.L.¹ Rack, M.F.² Simon, T.J.³

19
- 0032851480
- A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis
- For the Rofecoxib Osteoarthritis Endoscopy Study Group.
- (1999) Gastroenterology , vol.117 , pp. 776-783
- Laine, L.¹ Harper, S.² Simon, T.³

20
- 0034121667
- Comparison of the effect of rofecoxib (a cyclooxygenase-2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis. A randomized, double-blind, placebo-controlled trial
- For the Rofecoxib Osteoarthritis Endoscopy Multinational Study Group.
- (2000) Arthritis Rheum , vol.43 , pp. 370-377
- Hawkey, C.¹ Laine, L.² Simon, T.³

21
- 0033601079
- Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
- (1999) JAMA , vol.282 , pp. 1929-1933
- Langman, M.J.¹ Jensen, D.M.² Watson, D.J.³

22
- 0007101332
- Vioxx (rofecoxib). Medical Officer Review. Food and Drug Administration, Division of anti-inflammatory, analgesics and ophthalmic drug products - HFD-550. Rockville: FDA, 19/5/99.

23
- 0003177820
- Current problems in pharmacovigilance: Committee on Safety of Medicines. Medicines Control Agency. In Focus: Rofecoxib (Vioxx).
- (2000) Curr Probl Pharmacovigilance , vol.26 , pp. 13

24
- 0007002935
- Celebrex. Summary of Product Characteristics, UK. Searle, May
- (2000)

25
- 0033524421
- Systemic biosynthesis of prostacyclin cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
- (1999) Proc Natl Acad Sci USA , vol.96 , pp. 272-277
- McAdam, B.F.¹ Catella-Lawson, F.² Mardinin, I.A.³ Kapoor, S.⁴ Lawson, J.A.⁵ FitzGerald, G.A.⁶

26
- 0033665248
- Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: A randomized, controlled trial
- (2000) J Clin Pharmacol , vol.40 , pp. 124-132
- Leese, P.T.¹ Hubbard, R.C.² Karim, A.³ Isakson, P.C.⁴ Yu, S.S.⁵ Geis, G.S.⁶

27
- 0031680203
- Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor
- (1998) Arthritis Rheum , vol.41 , pp. 1591-1602
- Simon, L.S.¹ Lanza, F.L.² Lipsky, P.E.³

28
- 0034090905
- Treatment of osteoarthritis with a once-daily dosing regimen of celecoxib. A randomized, controlled trial
- (2000) J Clin Rheumatol , vol.6 , pp. 65-74
- Williams, G.W.¹ Ettlinger, R.E.² Ruderman, E.M.³

29
- 0033507971
- Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized controlled trial
- (1999) Mayo Clin Proc , vol.74 , pp. 1095-1105
- Bensen, W.G.¹ Fiechtner, J.J.² McMillen, J.I.³

30
- 0033601089
- Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. A randomized controlled trial
- (1999) JAMA , vol.282 , pp. 1921-1928
- Simon, L.S.¹ Weaver, A.L.² Graham, D.Y.³

31
- 0033582115
- Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomised double-blind comparison
- (1999) Lancet , vol.354 , pp. 2106-2111
- Emery, P.¹ Zeidler, H.² Kvein, T.K.³

32
- 0033843672
- Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo
- (2000) J Rheumatol , vol.27 , pp. 1876-1883
- Bensen, W.G.¹ Zhao, S.Z.² Burke, T.A.³

33
- 0033930616
- Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor
- (2000) Am J Gastroenterol , vol.95 , pp. 1681-1690
- Goldstein, J.L.¹ Silverstein, F.E.² Agrawal, N.M.³

34
- 0034644396
- Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: A randomized controlled trial
- (2000) JAMA , vol.284 , pp. 1247-1255
- Silverstein, F.E.¹ Faich, G.² Goldstein, J.L.³

35
- 0000278534
- Early experience with selective COX-2 inhibitors: Safety profile in over 340,000 patient years of use
- [poster]
- (1999) American College Rheumatology Annual Meeting , pp. 1352
- Singh, G.¹ Ramey, D.R.² Triadafilopoulos, G.³

36
- 0001855825
- Celecoxib: Early Australian reporting experience
- (2000) Aust Adv Drug React Bull , vol.19 , pp. 6-7

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.